JP6680774B2 - ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体 - Google Patents

ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体 Download PDF

Info

Publication number
JP6680774B2
JP6680774B2 JP2017518397A JP2017518397A JP6680774B2 JP 6680774 B2 JP6680774 B2 JP 6680774B2 JP 2017518397 A JP2017518397 A JP 2017518397A JP 2017518397 A JP2017518397 A JP 2017518397A JP 6680774 B2 JP6680774 B2 JP 6680774B2
Authority
JP
Japan
Prior art keywords
group
groups
alkyl
acid
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017518397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519821A (ja
JP2017519821A5 (enExample
Inventor
成徳 呉
成徳 呉
涛 于
涛 于
曙輝 陳
曙輝 陳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6680774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2017519821A publication Critical patent/JP2017519821A/ja
Publication of JP2017519821A5 publication Critical patent/JP2017519821A5/ja
Application granted granted Critical
Publication of JP6680774B2 publication Critical patent/JP6680774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017518397A 2014-06-17 2015-06-16 ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体 Active JP6680774B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201410271282.9 2014-06-17
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (3)

Publication Number Publication Date
JP2017519821A JP2017519821A (ja) 2017-07-20
JP2017519821A5 JP2017519821A5 (enExample) 2018-06-28
JP6680774B2 true JP6680774B2 (ja) 2020-04-15

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518397A Active JP6680774B2 (ja) 2014-06-17 2015-06-16 ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102731762B1 (ko) * 2015-12-16 2024-11-18 치아타이 티안큉 파마수티컬 그룹 주식회사 피리도[1,2-a]피리미돈 유사체, 이의 결정형, 이의 중간체 및 이의 제조방법
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
JP7331116B2 (ja) * 2019-01-24 2023-08-22 チアンスー アオサイカン ファーマシューティカル カンパニー，リミティド ＴＧＦ－βＲ１キナーゼ阻害剤としての５－（４－ピリジルオキシ）ピラゾール類化合物
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
JP2023512724A (ja) * 2020-02-10 2023-03-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用
WO2021180111A1 (zh) 2020-03-10 2021-09-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
AU2021344385A1 (en) 2020-09-15 2023-05-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369370T1 (de) * 2003-10-10 2007-08-15 Pfizer Prod Inc Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
JP5642963B2 (ja) * 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ，インコーポレイティド ピリジノニルｐｄｋ１阻害剤
WO2009055418A1 (en) * 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
US8415376B2 (en) * 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
NZ604478A (en) * 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777B (zh) 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Also Published As

Publication number Publication date
EP3159341B8 (en) 2020-01-08
WO2015192760A1 (zh) 2015-12-23
EP3159341A1 (en) 2017-04-26
CN106470992A (zh) 2017-03-01
KR20170016465A (ko) 2017-02-13
CN106470992B (zh) 2018-11-06
AU2015276699B2 (en) 2019-10-10
US20170137420A1 (en) 2017-05-18
ES2754264T3 (es) 2020-04-16
TW201625612A (zh) 2016-07-16
KR102495840B1 (ko) 2023-02-03
CA2951971A1 (en) 2015-12-23
TWI628180B (zh) 2018-07-01
CA2951971C (en) 2024-09-10
EA032642B1 (ru) 2019-06-28
US9856256B2 (en) 2018-01-02
EP3159341B1 (en) 2019-08-21
JP2017519821A (ja) 2017-07-20
AU2015276699A1 (en) 2017-01-19
EA201790016A1 (ru) 2017-06-30
EP3159341A4 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
JP6680774B2 (ja) ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
EP3159342B1 (en) Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
WO2012098068A1 (en) Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
AU2016254385A1 (en) JAK inhibitors
KR20230104782A (ko) Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물
EP4267137A1 (en) Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
CN118974050A (zh) 作为ras信号转导调节剂的稠合杂环化合物
HK1238629B (zh) 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物
HK1244803B (zh) 作为抗癌药物的取代的2-氢-吡唑衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170217

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200319

R150 Certificate of patent or registration of utility model

Ref document number: 6680774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250